Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy | Journal of Clinical Pathology

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via ACP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

For authors

About

Topic collections
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via ACP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Citation Tools

Short report

Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Kudesia G, Partridge S, Farrington CP, et al

Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy

Journal of Clinical Pathology 2002;55:154-155.